FREEDOM OF INFORMATION

REF: 2026-44
Subject: Acute Myeloid Leukaemia (AML) Patients

Dear Sir/Madam,

Thank you for your email dated **14/01/2026** where you requested information about **Acute Myeloid Leukaemia (AML) Patients.**

The information you requested is enclosed.

Question	Answer
1. How many patients have been diagnosed with Acute Myeloid Leukaemia (AML) at your Trust in the last 12 months	In 2025 we had total of 16 patients with acute myeloid leukaemia diagnosed and managed in our hospital. This doesn't include patients diagnosed in Bolton and transferred to other hospital for intensive chemotherapy
a. Of these patients how many are refractory/relapsed (R/R)?	<5. <5 had relapsed/refractory disease after intensive chemotherapy
b. How many of the R/R patients were FLT3 positive?	None (0)
2. How many patients have been treated for AML in the latest 12 months with the following treatments (Time period 01/01/25 and 31/12/25)	
• Venetoclax with azacitidine	7
• Midostaurin	0
• Quizartinib	0
• Gemtuzumab	0
• Ivosidenib with azacitidine	0
• Liposomal cytarabine-daunorubicin	0
• Oral azacitidine	<5
• Gilteritinib	0
• Palliative care	<5
• Enrolled in a clinical trial	0
3. How many relapsed/refractory patients have been treated for AML in the last 12 months with the following treatments (This question relates to treatments administered to relapsed/refractory AML patients in clinical practice, regardless of licence status or funding route (including any off-label use).	

• Venetoclax with azacitidine	<5
• Midostaurin	0
• Quizartinib	0
• Gemtuzumab	0
• Ivosidenib with azacitidine	0
• Liposomal cytarabine-daunorubicin	0
• Oral azacitidine	0 (<5 were on maintenance oral azactidine when they relapsed)
• Gilteritinib	0
• Palliative care	<5
• Enrolled in a clinical trial	0
4. Of your AML patient how many were tested as below in the last 12 months	
• Received an FLT3 mutation test when they were diagnosed	14
• Received an FLT3 mutation test when their disease relapsed	<5 (all patients with relapsed disease)
• Received an FLT3 mutation test when their disease became refractory	<5

If you have any queries or concerns please do not hesitate to contact the Freedom of Information Department. It would be helpful to quote the above reference number in any future communication.

If you are unhappy with the service you have received in relation to your request and wish to make a complaint or request a review of our decision, you should write to The Chief Executive, Bolton NHS Foundation Trust, The Royal Bolton Hospital, Minerva Road, Farnworth, Bolton. BL4 0JR.

If you are not content with the outcome of your complaint you may apply directly to the Information Commissioner. Generally the Information Commissioner cannot make a decision unless you have exhausted the complaints procedure provided by Bolton NHS Foundation Trust. The Information Commissioner can be contacted at The Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire. SK9 5AF.

The information supplied to you continues to be protected by the Copyright Design and Patents Act 1998. You are free to use it for your own purposes, including any non-commercial research you are doing and for the purposes of news reporting. Any other reuse, for example commercial publication requires the permission of the Trust. You must ensure you gain the Trust permission before reproducing any third party information.

Yours sincerely,

Information Governance Department

Bolton NHS Foundation Trust
01204 390861
FOI@boltonft.nhs.uk
Informatics Building | Opposite N Block | Royal Bolton Hospital

Improving care,
transforming lives...for a better Bolton

Improving care,
transforming lives...for a better Bolton